Press release content from Business Wire. The AP news staff was not involved in its creation.
Life Spine Announces Over 20,000 Units Sold of the PROLIFT® Expandable System
January 5, 2021 GMT
HUNTLEY, Ill. (BUSINESS WIRE) Jan 5, 2021
Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the Company has sold over 20,000 PROLIFT Expandable Implants.
“Expandable technology is on track to make up almost half of the domestic interbody market in the next five years 1 and we pride ourselves on having some of the oldest and broadest intellectual property encapsulating expandable spine technology,” said Michael Butler, President and CEO of Life Spine. “The rapid adoption of our Micro Invasive expandable portfolio is a direct result of our commitment to constantly innovate and create products designed to optimize spine surgery.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research .
Tonix Pharmaceuticals Holding Corp.January 5, 2021 GMT
Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation
TNX-1500 May Hold Potential in Treating Autoimmune Diseases Including Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis
CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a second research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody (mAb) that targets the CD40-ligand (also known as CD154, T-BAM or 5c8 antigen1) for the prevention and treatment of organ trans
Press release content from PR Newswire. The AP news staff was not involved in its creation.
VOLTA MEDICAL raises 28 million USD to revolutionize persistent AFib ablation
January 5, 2021 GMT
Volta Medical logo
MARSEILLE, France, Jan. 5, 2021 /PRNewswire/ Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 28 million USD. The financing round was led by Gilde Healthcare with participation of existing shareholder Pasteur Mutualité. The new capital will allow the company to establish its revolutionary FDA-cleared and CE marked VX1 AI software solution as a new standard of care, pursue further R&D activities and start to roll out commercial activities across the US and Europe. Recruitment for TAILORED-AF, an international multicenter trial has already started. Volta Medical will be welcoming two new Board members. Janke Dittmer, General Partn